Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Subscribe To Our Newsletter & Stay Updated